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Abstract
Background: Severe early onset (less than 34 weeks gestation) intrahepatic cholestasis of pregnancy (ICP) affects
0.1% of pregnant women in Australia and is associated with a 3-fold increased risk of stillbirth, fetal hypoxia and
compromise, spontaneous preterm birth, as well as increased frequencies of pre-eclampsia and gestational diabetes.
ICP is often familial and overlaps with other cholestatic disorders.
Treatment options for ICP are not well established, although there are limited data to support the use of
ursodeoxycholic acid (UDCA) to relieve pruritus, the main symptom. Rifampicin, a widely used antibiotic including
in pregnant women, is effective in reducing pruritus in non-pregnancy cholestasis and has been used as a
supplement to UDCA in severe ICP. Many women with ICP are electively delivered preterm, although there are no
randomised data to support this approach.
(Continued on next page)
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Methods: We have initiated an international multicentre randomised clinical trial to compare the clinical efficacy of
rifampicin tablets (300 mg bd) with that of UDCA tablets (up to 2000 mg daily) in reducing pruritus in women with
ICP, using visual pruritus scores as a measuring tool.
Discussion: Our study will be the first to examine the outcomes of treatment specifically in the severe early onset
form of ICP, comparing “standard” UDCA therapy with rifampicin, and so be able to provide for the first-time high-
quality evidence for use of rifampicin in severe ICP. It will also allow an assessment of feasibility of a future trial to
test whether elective early delivery in severe ICP is beneficial.
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Background
Intrahepatic cholestasis of pregnancy (ICP) is the most
frequent liver disorder specific to pregnancy, with an an-
nual Australian incidence of 0.6–0.8% [1]. Its cardinal
features are maternal pruritus and increased serum bile
acids (BA), commonly towards the end of the third
trimester. The pruritus, though often mild, can occasion-
ally be extremely severe, causing major skin excoriations,
profound sleep disturbances and associated psychopath-
ology, with iatrogenic premature delivery for symptom
relief. ICP can also cause severe liver dysfunction and
jaundice. BA are formed in the liver and secreted in the
bile into the intestine, where they emulsify fat in the
ingested food and enable its uptake into the liver, where
the BA are recycled. In ICP, this cycle of “enterohepatic
circulation” is inhibited and serum BA concentrations
increase, providing a marker for the disorder [2]. In-
creased rates of postpartum haemorrhage (PPH) re-
ported in early studies [3] have not been confirmed in
more recent larger datasets [4]. Gallstones may be
present more often in these women [5]. Women with
hepatitis C infection have a higher incidence of ICP [6].
Maternal symptoms typically resolve after birth, but af-
fected women have an increased risk of hepatobiliary
disease in later life [6]. There are few data for long term
outcome in the children of mothers with ICP [7].
ICP has been associated with increased fetal risks, in-
cluding spontaneous preterm birth, fetal hypoxia and
compromise (including meconium-stained liquor) and
unexpected intrauterine fetal death [3]. Higher concen-
trations of circulating BAs are associated with increased
fetal risks, including spontaneous preterm birth, asphyx-
ial events and stillbirth [8, 9]. Early onset (less than 34
weeks gestation) severe (defined as serum BA > 40 μmol/
L) ICP is a rare disorder with an Australian incidence of
0.1% per annum [1].
The aetiology of ICP has been linked to increased con-
centrations of oestradiol, progesterone and, in particular,
of progesterone metabolites in pregnancy, which impact
the farnesoid X receptor (FXR)-mediated BA homeosta-
sis pathways [10]. Why only some women develop ICP
may be attributable to genetic variants of the genes
encoding biliary transporters, eg phosphatidyl-choline
floppase multidrug resistance protein 3 (MDR3; ABCB4),
Bile Salt Export Pump (BSEP; ABCB11), phosphatidyl
serine flippase (ATP8B1), the multidrug resistance-
associated protein 2 (MRP2; ABCC2), and also tight
junction protein 2 (TJP2), [11] together with FXR, which
is critical in the transcriptional activation of both
ABCB11 [12] and ABCB4 [13]. Further evaluation of
genetic variants that confer ICP susceptibility may allow
precision medicine in the identification of women at in-
creased risk of adverse pregnancy outcome, and also
those more likely to respond to targeted treatment of
ICP with specific drugs.
A number of agents from different pharmacological
classes have been used in the management of women
with ICP. These include: ursodeoxycholic acid (UDCA),
cholestyramine, dexamethasone, s-adenosylmethionine
and, most recently, rifampicin. None are based on high
level evidence and, as a consequence, there are various
concerns over costs, side effects and possible harms. The
publication of the PITCHES study, a placebo-controlled
RCT of UDCA in 605 women with ICP of any severity
recruited between 20 and 40+ 6 weeks gestation, has con-
firmed a small reduction in pruritus for UDCA but no
benefit in respect of a composite of adverse perinatal
outcomes [14]. Pharmacological treatment of ICP is the
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subject of a 2020 Systematic Review in the Cochrane Li-
brary [15]. Included in this review were 26 randomised
controlled trials involving 2007 participants. The trials
were mostly at moderate to high risk of bias. Compared
with placebo, the pooled results showed a probable small
improvement in pruritus score measured on a 100 mm
visual analogue scale (VAS) (mean difference (MD) −
7.64 points, 95% confidence interval (CI) − 9.69 to − 5.60
points for UDCA in two trials (715 women) (GRADE
moderate certainty). The evidence for fetal compromise
and stillbirth were uncertain, due to serious limitations
in study design and imprecision (risk ratio (RR) 0.70,
95% CI 0.35 to 1.40; 6 trials, 944 women; RR 0.33, 95%
CI 0.08 to 1.37; 6 trials, 955 women; GRADE very low
certainty).
Understanding of the mechanism of action of the vari-
ous drugs is limited. Ursodeoxycholic acid (UDCA) is a
naturally occurring BA, which displaces more hydropho-
bic endogenous bile salts from the BA pool. This action
may shield the hepatocyte membrane from the damaging
toxicity of bile salts, enhancing BA clearance across the
placenta from the fetus [16]. UDCA has also been shown
in vitro to protect rat cardiomyocytes from damage by
endogenous bile salts [17].
Since the publication of the previous Cochrane review
in 2013 [18], there has been increasing interest in the
use of rifampicin in treating women with ICP. Rifampi-
cin is a semisynthetic antibiotic with a wide range of
antimicrobial activity and is a first-line agent for
treatment of tuberculosis, including for treatment of
pregnant women [19, 20]. Rifampicin has also been
shown to have the capacity to reduce serum BA in the
management of cholestasis outside of pregnancy. It is a
pregnane X-receptor (PXR) agonist and a potent inducer
of key enzymes in the hepatic and intestinal detoxifica-
tion machinery (such as CYP3A4, CYP2D, UGT1A1,
SULT2A1) and export pump MRP2 [21]. A systematic
review of pharmacological interventions for pruritus in
palliative care showed that, in patients with cholestatic
pruritus, data favoured the use of rifampicin, showing a
low incidence of adverse events when compared with
placebo [22]. There have been no reported trials com-
paring UDCA and rifampicin in the treatment of prur-
itus in any clinical scenario. Rifampicin has no known
teratogenic effects, although an effect on vitamin K me-
tabolism mandates parenteral neonatal administration of
vitamin K [23]. In a questionnaire survey of clinicians,
who reported results on 27 women with 28 affected
pregnancies identified via the International Obstetric
Medicine forum: the clinical case notes of women with
ICP treated with UDCA and rifampicin were reviewed,
and data regarding maternal and perinatal outcomes
were extracted [24]. While serum BA remained high
whilst taking UDCA as monotherapy, use of rifampicin
led to reductions in serum BA in more than half the
women, and to halving of serum BA in more than 33%.
No adverse effects were reported with either drug. There
were no stillbirths and no postpartum haemorrhage re-
ported, but the numbers were very small.
Data from The Netherlands suggest that rifampicin
may be a more appropriate therapy for individuals with
ABCB11 mutations associated with clinical BSEP defi-
ciency and Benign Recurrent Intrahepatic Cholestasis
(BRIC) outside of pregnancy [25]. Recent data from
France, on the other hand, while supporting the use of
UDCA in ICP, did not show any relation of ABCB4 mu-
tations to treatment with UDCA [26].
Other strategies to improve outcomes for pregnant
women have focussed on the timing of birth. A trial
involving 62 women with ICP (any gestation or sever-
ity) compared early term delivery (induction or deliv-
ery started between 37+ 0 and 37+ 6 weeks gestation)
versus expectant management (spontaneous labour
awaited until 40 weeks gestation or caesarean section
undertaken for normal obstetric indications, usually
after 39 weeks gestation). There were no stillbirths or
neonatal deaths in either group. No clear differences
in caesarean section, passage of meconium-stained li-
quor or admission to neonatal intensive care unit
were observed [27]. Despite the lack of RCT evidence
to support benefit for early delivery and potential
harms, many centres around the world have adopted
a practice of ensuring birth for women by 37 weeks
gestation, particularly of women with severe ICP, to
avoid the increased risk of stillbirth [28].
We have therefore planned a series of trials to answer
some of these important clinical questions, using a simi-
lar plan as the protocol for the prospective STRIDER
studies [29]. In this initial study, we compare the use of
rifampicin vs UDCA in women with severe early onset
ICP. The trial has as its primary outcome pruritus, an
important clinical endpoint for the women affected,
which can be measured easily and effectively with a well-
validated visual scale as a continuous variable. It also al-
lows a much smaller sample size in a superiority design
than that required to demonstrate differences in peri-
natal morbidity and mortality. The results of the trial
will then be able to be compared, subject to HREC and
local governance approval after submission of a separate
protocol, data sharing agreements and appropriate de-
identification of the data, in a meta-analysis with the re-
sults from the PITCHES trial to give a robust estimate
of the sample size required to conduct a definitive
clinical trial with serious perinatal morbidity and mortal-
ity as major outcomes.
Our study will be the first to examine the outcomes
of treatment specifically in the severe early onset
form of ICP, comparing “standard” UDCA therapy
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with rifampicin, and so be able to provide for the




The primary trial hypothesis is that rifampicin, com-
pared with UDCA treatment of women with severe early
onset ICP, commenced between 14+ 0 and 33+ 6 weeks of
gestation, reduces the degree of pruritus, measured as
worst itch in the previous 24 h assessed on a patient-
recorded visual analogue scale.
Secondary trial hypotheses include:
Rifampicin, compared with UDCA, improves short-
term outcomes for both mother and infant in severe
early onset ICP, including the length of gestation and
the incidence of caesarean section and preterm birth.
Rifampicin, compared with UDCA, improves markers
of maternal liver function in severe early onset ICP,
including serum BA and serum transaminase
concentrations.
Trial design
TURRIFIC is a multicentre randomised open label con-
trolled study to evaluate whether rifampicin is superior
to UDCA in the reduction of pruritus in parallel groups
of women with severe ICP presenting between 14+ 0 and
33+ 6 weeks gestation. Initial random allocation to treat-
ment with rifampicin or UDCA is in a ratio of 1:1.
Trial setting
The study is being conducted in11 academic hospital
centres across Australia and internationally in the UK,
Sweden, Finland and The Netherlands. [See list at www.
adelaide.edu.au/TURRIFIC].
Participants
Potentially eligible participants are identified via ante-
natal clinics, antenatal assessment units and antenatal
wards and by review of laboratory BA results.
Women attending for management of severe early on-
set ICP are invited by the treating physician/obstetrician
to consider participation in the study, and if agreeable,
provide written informed consent to participate.
Inclusion criteria
Women are considered eligible for inclusion into the
trial with the following criteria:
 Severe ICP (defined as pruritus with increased total
serum BA ≥40 μmol/L) confirmed
 Viable pregnancy between 14+ 0 and 33+ 6 weeks
gestation inclusive (as determined by ultrasound
pregnancy dating)
 No known lethal fetal anomaly
 Singleton pregnancy
 Obstetric care in a consultant-led unit
 Aged 18 years or over
 Written informed consent has been obtained
Standardisation of serum BA concentration measure-
ments: participating units will have tested a series of
serum samples sent out from Adelaide, for comparison
and correlation with the Adelaide values, and subse-
quent adjustment of the results from the local laborator-
ies to enable standardisation of the results across the
trial. Similar quality control testing will be carried out
every 12 months.
Women who present with non-severe ICP (total serum
BA < 40 μmol/L) between 14+ 0 and 33+ 6 weeks gesta-
tion, and who then progress, with or without UDCA
treatment, to severe ICP (total serum BA ≥40 μmol/L)
prior to 34+ 0 weeks gestation, are eligible for entry into
the trial, providing they are willing to accept random al-
location to treatment (with a wash-out period of any
pre-existing UDCA treatment for 4–7 days to enable
baseline biochemical data to be obtained, and confirm
eligibility only if serum BA were measured ≥40 μmol/L
while not taking UDCA), they meet the other inclusion
criteria and they do not meet any of the exclusion cri-
teria (below), in which case they will be randomised ei-
ther to rifampicin therapy or to commence/continue
with UDCA therapy.
Exclusion criteria
A potential participant who meets any of the following
criteria will be excluded from participation in this study:
 A decision has already been made for delivery within
the next 48 h
 There is allergy to any component of the UDCA or
rifampicin tablets
 The woman is taking other medication that has a
significant interaction with rifampicin treatment,
including saquinavir and ritonavir in combination
for treatment of HIV, daclatasvir, simeprevir,
sofosbuvir and/or telaprevir for treatment of
hepatitis C, isoniazid and/or pyrazinamide for
treatment of tuberculosis
 General anaesthesia within the previous 3 months to
avoid the risk of inadvertent and unrecognised
previous halothane exposure
 There is a multi-fetal gestation
 There is laboratory-confirmed active hepatitis A or
hepatitis B, or positive serology for hepatitis C
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 There is current pre-eclampsia (ISSHP criteria) [30]
 There is a known active primary hepatic disorder,
including α-1-antitrypsin deficiency and auto-
immune hepatitis, including primary biliary
cholangitis
 The woman is currently taking medication, which
causes deranged liver enzyme values
 The woman is unwilling for her baby to have
standard vitamin K administration at birth
 The woman has previously participated in
TURRIFIC
A woman will not be excluded, and may be rando-
mised, if she is known to have:
 A known genetic disorder associated with
cholestasis
 Asymptomatic cholelithiasis (no colicky right upper
quadrant pain/jaundice)
 Current gestational diabetes (GDM) (WHO criteria)
[31]
Interventions
The intervention under test is rifampicin (rifampicin)
tablets 300mg twice daily and the comparator treatment
is ursodeoxycholic acid (UDCA) tablets up to 2000 mg
daily, prescribed as per the usual local protocols.
Women meeting the inclusion criteria and consenting
to participation will be randomly allocated to treatment
with rifampicin or UDCA at study entry. The duration
of treatment will range from 1 day to a maximum of 28
weeks, for a participant randomised at 14 weeks who
does not deliver until 42 weeks.
Within the trial, both UDCA and rifampicin are usu-
ally dispensed by the local hospital pharmacy.
Ursodeoxycholic Acid (UDCA)
There are no known drug contraindications to UDCA.
The starting dose of UDCA is 450-1000 mg daily (450
mg or 500 mg tablets as per local pharmacy stock to be
taken once daily or twice daily), increased in increments
of 500 mg per day every 3–14 days, if there is no bio-
chemical/clinical improvement, up to a maximum of
2000 mg per day [32]. UDCA will be continued until
birth and then discontinued, or it may be weaned at the
discretion of the treating clinician.
Possible side-effects
Common side effects include soft loose stools or
diarrhoea.
Less common side-effects include urticaria.
Rifampicin
The dose of rifampicin is 300 mg twice daily. Adminis-
tration of rifampicin will be withheld if, during treat-
ment, there is a rise of serum ALT above 200 U/L, and
the management of such patients discussed with senior
clinicians, including CI Hague and/or CI Williamson, to
decide about continuation of rifampicin therapy. Rifam-
picin will be weaned after birth by 150mg every 3 days.
Possible side-effects
Commonly, body fluids, including urine, stools, saliva,
sputum, sweat and tears, turn red-orange.
Other side effects from rifampicin are not common,
but can include headache, muscle pain, bone pain, heart-
burn, upset stomach, vomiting, stomach cramps, chills,
diarrhoea, urticaria, sores on skin or in the mouth, fever,
or jaundice.
Drug interactions
Halothane, listed in the Product Information as an ex-
clusion for rifampicin treatment, is not currently used in
the countries where the trial is being conducted. It is
possible that immigrant women may have been exposed
to halothane before arrival. All women being screened
for eligibility will be asked if they have had a general an-
aesthetic within the previous 3 months and, if so, they
will be excluded from the trial to avoid the risk of inad-
vertent and unrecognised previous halothane exposure.
It is most unlikely that women with active or currently
treated tuberculosis (TB) will be recruited to the trial,
but women taking isoniazid or pyrazinamide will not be
considered for inclusion.
Rifampicin can have significant interaction with other
drug therapies. In particular, it can interact with hormo-
nal contraceptive agents and appropriate advice will be
given in the postpartum period for those women who
have been taking rifampicin to take different or add-
itional contraceptive precautions for a month after ceas-
ing rifampicin therapy.
Current practice
Women who present with mild to moderate ICP remote
from term will usually be offered treatment with UDCA,
with ongoing surveillance in the obstetric and obstetric
medical clinics, and consideration given to delivery be-
tween 38 and 40 weeks gestation.
Women who present with, or who progress to, severe
ICP will usually be offered treatment with increasing
doses of UDCA, with the addition of rifampicin, if con-
sidered necessary, to reduce the serum BA concentra-
tions, even though this is not a standard indication.
Delivery will often be brought forward to between 36
and 37 weeks gestation, especially if there is subjective
reduction in fetal movements.
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Adherence to and returns of study treatment
Treatment adherence will be measured by review of the
medication dosing card and participant self-report at
each visit. Medication dosing cards will be collected
when they are completed and at the end of the study.
There is no compulsion to return any unused medica-
tion. However, study staff will offer to dispose safely of
any unused medications that the participant wishes to
relinquish.
Concomitant medication
All prescribed and “over the counter” medications
deemed necessary by an attending healthcare profes-
sional to provide adequate supportive care to the woman
are permitted during the trial. All medications taken by
the woman, including vitamin K and other supplements,
are to be recorded in the participant’s eCRF.
Women taking rifampicin and who are subsequently
commenced on medications known to have significant




Maternal pruritus score, measured as worst itch in the
previous 24 h assessed on a patient-recorded visual
analogue scale.
Secondary outcomes
The secondary short-term maternal outcomes are de-
fined as:
 Serial biochemical indices of disease: serum
concentration of bile acids (BA), bilirubin (total),
alanine transaminase (ALT), gamma glutamyl
transferase (GGT)
 Peak serum concentration (between randomisation
and delivery) of BA
 Maximum doses of trial medications required, and
days of such medications
 Days from randomisation to birth
 Days to resolution/amelioration of symptoms
 Need for added treatment with UDCA or rifampicin
as appropriate after 7 days of the randomly allocated
drug therapy
 Need for additional therapy at maximum trial
dosage (e.g. antihistamines, cholestyramine,
therapeutic plasma exchange/other)
 Incidence of gestational diabetes mellitus (WHO
criteria) and its treatment (diet/metformin/insulin),
and of gestational hypertension/pre-eclampsia
(ISSHP criteria)
 Upper abdominal ultrasound/biliary pathology
 Mode of onset of labour, and gestation at onset
 Timing of steroids (if any) for fetal pulmonary
maturation
 Duration of labour
 Presence of meconium in the liquor intrapartum
 Gestation at birth
 Mode of birth, classified as spontaneous vaginal,
instrumental vaginal or Caesarean
 Reason for induction or pre-labour Caesarean
section
 Estimated blood loss at birth
 Time for resolution of symptoms after birth
The secondary short-term perinatal outcomes are de-
fined as:
 Miscarriage (fetal death before 20+ 0 weeks
gestation)
 Stillbirth (death before delivery ≥20+ 0 weeks
gestation or > 400 g if gestation unknown)
 Neonatal death in hospital up to 7 days after birth
(excluding death due to congenital anomalies)
 Neonatal unit admissions until infant discharge
home from hospital
 Number of nights in each category of care
(intensive, high dependency, special, transitional and
normal) and total number of nights in hospital
 Birth weight (g), and customised/population birth
weight centile (GROW) [33]
 Apgar scores at 1 and 5 min after birth
 Umbilical arterial and venous pH (and base excess)
at birth
 Cord blood BA
 Need for supplementary oxygen prior to discharge,
and number of days when such oxygen is required
 Need for ventilation support (continuous positive
airway pressure - CPAP/high flow/endotracheal
ventilation)
 Pneumothorax (confirmed on chest X-ray)
 Need for phototherapy
 Abnormal cerebral ultrasound scan
 Confirmed sepsis (positive blood or cerebrospinal
fluid cultures)
 Necrotising enterocolitis (Bell’s stage 2 and 3)
 Seizures (confirmed by EEG or requiring
anticonvulsant therapy)
 Encephalopathy grade (worst at any time: mild,
moderate, severe)
 Hypoglycaemia (blood glucose < 2.6 mmol/l on two
or more occasions)
 Severe hypoglycaemia (blood glucose < 1.8 mmol/l
on two or more occasions)
 Other indications and main diagnoses resulting in
NNU admission.
 Mode of feeding at discharge from hospital
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The primary outcome, maternal pruritus score, will be
evaluated at 1 week after trial entry and then on a
monthly basis up to 28+ 0 weeks gestation and then
weekly to delivery.
The timepoints of evaluation of the secondary mater-
nal outcomes are at 1 week post-randomisation visit, at
monthly clinic visits at 20, 24 and 28 weeks gestation (if
randomised prior to that), at weekly clinic visits after 28
weeks gestation and during admission for birth, and of
the secondary neonatal outcomes at delivery and 1 week
and 6 weeks after birth.
The following information post enrolment will be cap-
tured for health resource use:
 Maternal: total number of nights (antenatal,
intrapartum and postnatal) together with level of
care including adult ICU.
 Infant: total number of nights for the baby in
neonatal unit, together with level of care (e.g.
neonatal ICU).
The costs of UDCA and rifampicin, together with the
costs of any additional treatment, will be calculated in
both the UDCA and rifampicin groups.
Main trial procedures (see timeline in Table 1)
Informed consent
Written informed consent will be sought from the
woman only after she has been given a full verbal ex-
planation (by a healthcare professional or research mid-
wife/assistant) and written description (via the most
recent approved version of the PICF in the local national
language). She will be given sufficient time to consider
the information, and the opportunity to question the PI
or other independent parties to decide whether she will
participate in the trial. Women who do not speak Eng-
lish, or the national language if in a non-Australian
centre, will only be approached if an interpreter is
available.
Women eligible for the trial, whether or not they par-
ticipate, will be asked about their willingness to take part
in a subsequent trial of planned delivery of such affected
women at 36+ 0 weeks gestation compared with expect-
ant management in terms of neonatal outcomes.
Women taking part in the study will be asked about
any other drugs that have been prescribed or initiated
after randomisation. If such medications include agents
known to have a significant interaction with rifampicin,
then a woman taking rifampicin will be asked to with-
draw from the study, although any data obtained until
withdrawal will be included, and any pregnancy outcome
data will be recorded (with her consent).
Participating women will also be asked at recruitment
about any antibiotics they may have taken in the 3
months prior to recruitment, as well as any progesterone
supplements they may have taken.
Sample size
It is planned to recruit 108 women in total.
Randomisation
Initial random allocation to treatment with rifampicin or
UDCA will be in a ratio of 1:1.
Randomisation is managed via a secure web-based
randomisation facility hosted on REDCap at The Univer-
sity of Adelaide, with telephone back-up available.
Stratification is by centre and by severity (serum BA
concentration prior to randomisation < 100 μmol/L,
≥100 μmol/L).
The woman is allocated a unique participant identifi-
cation number on randomisation.
Baseline assessments
Baseline data, including all demography, itch chart re-
sults, serum BA concentrations, other serum analytes,
viral serology and coagulation profiles, including pro-
thrombin time and activated partial thromboplastin time
(recorded within 7 days prior to randomisation, and 4–7
days after cessation of any previously initiated UDCA
therapy), are entered on the web-based data base. The
itch chart is a previously validated 100 mm visual
analogue score where the participant is asked to score
her worst itch in the previous 24 h [27]. All laboratory
data are measured in the routine hospital laboratories
for each centre.
Other biological samples, including serum, urine, fae-
ces, liquor and placenta, may also be collected (with par-
ticipant consent) under separate protocols and stored
for later assessment.
On completion of these details, the database issues a
randomisation notification to the site PI/delegate. A pre-
scription for the allocated study treatment is written by
the local PI or their delegate, using a standard clinical
prescribing script, and the participant collects the study
treatment from the pharmacy.
Subsequent visits
At the first visit a week after randomisation, and then at
least monthly, if randomised prior to 28 weeks gestation,
and then weekly thereafter, the woman is asked for a
value of the worst itch she felt during the previous 24 h,
which is then scored on the itch chart. Serum is drawn
and monitored for measurement of BA and liver bio-
chemistry and measurement of prothrombin time and
activated partial thromboplastin time (as per usual
clinical practice), together with any further biological
samples for later assessments (with the woman’s con-
sent) under separate protocols, together with routine
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cardiotocography and ultrasound monitoring (weekly
umbilical artery Doppler, 2-weekly growth parameters).
The dose of treatment is altered at the discretion of the
responsible clinician.
If maximal doses of primary drug therapy are reached,
consideration is given to the addition of, first UDCA or
rifampicin respectively, following measurement of any
appropriate biochemical and microbiological samples, to
enable the relevant comparisons to be drawn, and then
other therapy, eg cholestyramine, in addition to the trial
therapy.
Women in the study, whether randomised to either
UDCA or rifampicin, who develop steatorrhoea, are also
to be prescribed vitamin K supplements (10 mg daily) to
be taken until delivery.
Women may be prescribed pre-delivery antenatal ste-
roids for enhancing lung maturity at the discretion of
the treating clinician. Any such antenatal steroid therapy
will be recorded in the eCRF.
The remainder of antenatal care and, in particular, de-
cisions about the mode of birth as well as the
administration of steroids for promotion of fetal lung
maturity, is left to the discretion of the treating clinician.
All neonates, and especially those of women taking ri-
fampicin, are to be given parenteral Vitamin K at birth.
The post-delivery outcome will be completed after de-
livery and before the woman leaves hospital.
Participants will be asked to attend for follow-up at 6
weeks postpartum, with routine blood samples (includ-
ing BA measurement as well as OGTT, if appropriate)
collected 1–3 days beforehand.
Biological samples and laboratory tests
Routine biochemical, autoimmune and viral serology,
and coagulation testing as per local maternity unit
guidelines (commonly serum BA, liver biochemistry, in-
cluding ALT/GGT/bilirubin, viral serology including
hepatitis A, B, C, D, E and G (as per local guidelines),
cytomegalovirus (CMV), Epstein-Barr virus (EBV) and
herpes simplex (HSV), autoimmune liver serology (mito-
chondrial, smooth muscle, ANA and LKM antibodies)
and INR/APTT).
Table 1 Trial Timeline
GA gestational age, ALT alanine transaminase, LFTs liver chemistry analysis, INR/APTT International Normalised Ratio/Activated Partial Thromboplastin Time
Notes to Table 1
1All screening assessments are part of normal clinical practice
2Bile acid samples need to be drawn shortly before a scheduled dose of UDCA, though fasting is not required. Women previously prescribed UDCA for treatment
of mild ICP, and agreeing to randomisation, will have basal assessments performed 4–7 days after ceasing such therapy prior to randomisation into the trial
3Study treatment started after randomisation. Dose to be adjusted by PI if indicated by symptoms and/or blood tests taken during normal clinical practice
4Adverse events will be recorded from study entry until post-delivery discharge of woman and baby. All SAEs are to be reported to the Coordinating Centre
within 24 h of Investigator knowledge
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Serum BA do not need to be collected fasting but
should be collected shortly before the next scheduled
dose of UDCA, if being taken. Fasting/non-fasting and
the length of time since the last dose of UDCA should
be noted.
Withdrawal of participants
It will be made clear to participants that they remain
free to withdraw from the clinical trial at any time with-
out the need to provide any reason or explanation; and
that this decision will not impact on any aspect of their
ongoing clinical care. The investigator will be able to
discontinue participants from either of the study drugs
in the event that they judge that alternative treatment is
required, without the woman being necessarily with-
drawn from the study. Participants will not be with-
drawn for self-reported low or non-adherence to their
study treatment.
Permission will be sought to complete and use data up
to the point of withdrawal including both:
 trial specific data
 data collected as per routine clinical practice
Permission will also be sought to ascertain and record
subsequent perinatal outcome data.
The reason for withdrawal will be recorded in the
eCRF, and, if it was due to an Adverse Event, the investi-
gator will follow up to resolution/stability.
Similarly, it will also be made clear to participants that
they remain free to withdraw from any future sub-
studies to which they have agreed at any time without
the need to provide any reason or explanation; and that
such a decision will not impact on any aspect of their
ongoing clinical care.
Statistics
Rationale for sample size
One hundred eight women are required to have a 90%
chance of detecting, as significant at the 5% level, a de-
crease in maternal pruritus score from -16mm in the
UDCA group to -23 mm in the rifampicin group, (with a
standard deviation (SD) of 10 mm across both arms,
allowing for a 5% drop out in each arm).
The SD stipulated for the sample size calculation
might appear to be too small, on the basis of the values
reported in the PITCH study, in which UDCA reduced
itching by -16 mm (95% confidence interval -27 mm to
-6 mm) [27].. The estimate and 95% Confidence Interval
for the difference in pruritus score between the UDCA
and the Placebo group was -16 mm (-26.5, -5.9 mm).
This suggests that the standard error is approximately
5.3 mm, and hence the standard deviation of the
difference between the groups (given n = 55 and n = 56)
is approximately 28 mm.
The statistical power of the study, however, has been
calculated with the intended sample size of 108 (n = 54
per group), so as to detect a difference between UDCA
and rifampicin if the mean change in pruritus score in
the UDCA group is -16 mm (as reported in the PITCH
study versus placebo, where change in the placebo group
was negligible), while the mean change in pruritus score
in the rifampicin group is -30 mm (which has already
been stipulated as the minimum change that would be
considered clinically meaningful). These calculations
were done as the power for a simple comparison of two
means, and via simulation to allow for up to five mea-
surements per participant, with correlation between the
repeated measures, and show that there is approximately
75% power (with two-sided alpha 0.05) to detect a differ-
ence between the groups of this magnitude; i.e., if rifam-
picin achieves a clinically meaningful reduction in
pruritus score while UDCA achieves a reduction of the
magnitude reported in PITCH, there is 75% power to
detect this.
In the recent PITCHES study, however, the reduction
of pruritus score in the UDCA group was much more
modest (-5.7 mm) [14]. The CI gives a very similar SD,
i.e. 25 mm. This gives much greater power to detect a
difference between UDCA and rifampicin: if rifampicin
had a change of -23 mm, we have approx. 95% power,
and if it had a mean change of -30 mm, > 99% power.
The inclusion of multiple centres will enable max-
imum recruitment over a limited time scale.
Data analysis
A detailed Statistical Analysis Plan will be developed by
the trial statistician (who is independent of the Sponsor)
and agreed by the Trial Management Committee (TMC)
before the analysis is undertaken. The analysis and pres-
entation of results will follow the most up-to-date rec-
ommendations of the CONSORT group. Analyses will
be completed in STATA® version 13.0 or later.
All analyses will follow the intention to treat principle,
i.e. data from all randomised woman and babies will be
analysed according to the treatment they were allocated
to irrespective of the treatment they received or whether
they received any treatment at all.
Blinding will not be possible for participants and care
providers, because of the open nature of the interven-
tions, nor will the DSMC be blinded to allocation in
their assessment of outcomes and safety, but the out-
come data will be blinded to the data analysts by con-
cealing the group allocation prior to the analysis.
Demographic and clinical data will be summarised
with counts and percentages for categorical variables,
means (standard deviations) for normally distributed
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continuous variables and medians (with interquartile or
simple ranges) for other continuous variables.
For the primary outcome, the effectiveness of the in-
terventions will be assessed by calculating the differences
in mean pruritus score with 95% confidence intervals
(CI), determined with a linear regression model, using
Generalised Estimating Equations (GEEs).
All comparative analyses will be performed adjusting
for stratification variables and baseline measures of the
outcome, where relevant. Binary outcomes will be ana-
lysed using log binomial regression models. Results will
be presented as adjusted risk ratios plus 95% CIs. If the
model is unstable, log Poisson regression models with
robust variance estimation will be used [34]. Continuous
outcomes will be analysed using linear regression
models, and results will be presented as adjusted differ-
ences in means (with 95% CIs). Analysis of outcomes
that are measured repeatedly over time (severity of prur-
itus and biochemical markers) will use repeated mea-
sures analysis techniques, including GEEs and/or
random effects.
Pre-specified subgroup analysis
Pre-specified subgroup analyses will use the statistical
test for interaction and where appropriate, results will be
presented as differences in means with 95% CIs, and the
number needed to treat to benefit or harm calculated.
Pre-specified subgroups will be based on:
 Serum BA at baseline (< 100 μmol/L, ≥100 μmol/L).
 Site
Dealing with missing data
Missing data as a result of women or babies being lost
to follow-up are expected to be minimal. A sensitivity
analysis will be conducted on the primary outcome and
multiple imputation by the fully conditional specification
(chained equations) method will be used to impute miss-
ing outcome data.
Ethics & Regulatory Approvals
Declaration of Helsinki and guidelines for good clinical
practice
The trial is being conducted in compliance with the
principles of the Declaration of Helsinki (1996), the ICH
guidelines of Good Clinical Practice (GCP) and in ac-
cordance with all applicable regulatory requirements.
Approvals
The trial has started after gaining approval from the reg-
istered HREC of the Women’s and Children’s Health
Network and other relevant regulatory authorities, in-
cluding the Therapeutic Goods Administration (TGA)
(Australia), the Medicines and Healthcare products
Regulatory Authority (MHRA) (UK) and the European
Medicines Agency (EMA). Additionally, approval of local
health service Research Offices is being sought for indi-
vidual trial sites.
Participant confidentiality, data handling and record
keeping
Overall responsibility for ensuring that each participant’s
information is kept confidential lies with the Site Investi-
gator. All paper documents are being stored securely
and kept in strict confidence in compliance with the
Data Protection Act (1998) and all trial data are being
stored in line with the UK Medicines for Human Use
(Clinical Trials) Amended Regulations 2006) as defined
in the KHP-CTO Archiving Standard Operating Proced-
ure (SOP).
Data entered onto the eCRFs are being downloaded
for storage and analysis into an electronic database held
by The University of Adelaide in which the participant is
identified only by a trial specific number and their ini-
tials. The participant’s name and any other identifying
details are being stored in a separate database main-
tained by the site which will be linked only to the data-
base containing study data by the participant’s trial
number.
Electronic files are being stored on a file server that
has restricted access. Data are being processed on a
workstation by authorised staff. The computer worksta-
tions access the network via a login name and password
(changed regularly). No data are stored on individual
workstations. Backing up is done automatically overnight
to an offsite storage area.
After the trial has been completed and the reports
published, the data will be archived in a secure physical
or electronic location with controlled access by permis-
sion of the chief investigator and/or the TMC.
The trial data will be made available to appropriate
academic parties on request from the chief investigator,
in accordance with the data sharing policies of The Uni-
versity of Adelaide, with input from the TMC where ap-
plicable, subject to submission of a suitable study
protocol and analysis plan, on publication of all initial
trial results.
Retention of personal data
Personal data will be needed to disseminate the results
of the trial to the participants. Due to the nature of preg-
nancy research, data will be kept for a period of up to
30 years (per local site requirements) in order to follow-
up on health-related issues which may become relevant
in the future. At all times the personal data are to be
held securely and will not be used for any other purpose.
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Protocol amendments
Any important protocol amendments (eg, changes to eli-
gibility criteria, outcomes, analyses) will be disseminated
to relevant parties (eg, TMC, DSMC, HRECs, trial par-
ticipants, trial registries, regulators) as necessary.
Assessment and reporting of safety
Assessment and reporting of adverse events and safety
outcomes will follow the reporting guidelines and defini-
tions of the NHMRC.
Expected events
The following are considered as expected occurrences in
this population of pregnant women or a result of the
routine care/treatment of a participant. As such, they
will be recorded on the eCRF but not reported as AEs or
SAEs:
 Worsening pruritus
 Hospitalisation for worsening ICP
 Gestational diabetes/diabetes stabilisation
 Pre-eclampsia
 Admission in active labour
 Admission for cervical ripening or induction of
labour
 Admission for caesarean section
 Short term (< 24 h) admission for assessment for
suspected fetal compromise, including reduced fetal
movements, or accelerated fetal growth and/or
polyhydramnios
 Short term (< 24 h) admission for monitoring for
hypertension, suspected preterm labour, or pre-
labour rupture of the membranes
Such admissions are not AEs, but the underlying rea-
son may be.
However, admission for other fetal or maternal issues,
including IUGR, reduced movements, severe hyperten-
sion, seizures (eclampsia), antepartum haemorrhage,
pre-term labour, pre-term premature rupture of the
membranes (PPROM), psychiatric disorder, social issues,
unstable lie/abnormal lie, amnioreduction, and other is-
sues are to be reported as AEs, and may well be consid-
ered SAEs, especially if the admission is for > 24 h.
The following perinatal outcomes are pre-specified
outcomes and will not be reported as AEs/SAEs:
 NNU admission
 Preterm delivery (< 37 completed weeks gestation)
 Meconium staining of the amniotic fluid or placenta
 Need for phototherapy
 Need for respiratory support – headbox oxygen
The following perinatal complications are to be re-
ported as AEs and may be considered as SAEs:
 Neonatal seizures
 Encephalopathy treated with hypothermia
 Need for respiratory support – ventilation via an
endotracheal tube or nasal CPAP
 Sepsis requiring > 5 days antibiotics with symptoms
or confirmed blood or cerebro-spinal fluid (CSF)
culture
The period for safety reporting is from first dose of
study treatment until 6 weeks post-delivery.
Procedures for recording AEs
Assessment for AEs are to be conducted at each study
visit. All AEs occurring during the trial that are observed
by the PI/delegate or reported by the participant will be
recorded in the eCRF, whether or not attributed to the
study drug. In recording the AE on the eCRF, whether
the event was an SAE or not will be entered. All AEs de-
termined to be an SAE must be reported following the
guidelines and time frames below.
All AEs and SAEs will be followed-up to resolution
with a start date and an end date recorded.
It will be left to the PI’s clinical judgement to decide
whether or not an AE is of sufficient severity to require
the participant’s removal from the trial. A participant
may also voluntarily withdraw from treatment due to
what she perceives an intolerable AE. If either of these
occurs, the participant must be given appropriate care
until symptoms cease or the condition becomes stable.
Unexpected serious adverse maternal and neonatal
events (SAEs) will be reported to the sponsor within 24
h. The sponsor will forward these reports and their re-
view of the SAE to the DSMC and the HREC that pro-
vided REC approval within 72 h of receipt.
Treatment stopping rules
After inclusion of 50 women in the cohort, the DSMC
will assess safety issues to ensure there is no convincing
evidence of harm in either arm of the study. The DSMC
will, if appropriate, make recommendations regarding
continuance of the study or modification of the study
protocol.
The trial management committee (TMC) has ultimate
responsibility for deciding whether a trial should be
stopped on safety grounds and will meet regularly to en-
sure recruitment milestones are met (see milestones).
If the trial is prematurely discontinued, active partici-
pants will be informed and no further participant data
will be collected. The Competent Authority (CA) and all
relevant HRECs will be informed within 15 days of the
early termination of the trial.
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Quality control and assurance
Initiation of each participating centre will be performed
by the chief investigator or their delegate once all appro-
priate approvals are in place. During the trial, ongoing
on-site and central monitoring will be conducted. The
site principal investigator (PI), research assistant and
their delegates from each centre will be fully trained in
protocol adherence and able to deal with site-specific is-
sues. They will then be responsible for delivering this
training to all relevant site staff prior to opening their
centre for recruitment. The PI and research midwife will
also promote the trial and ensure that all appropriate
site staff are kept fully appraised of issues such as re-
cruitment status, informed consent, data collection,
follow-up and changing regulations, so that the neces-
sary recruitment targets are reached within the
timescale.
The trial coordinator will monitor recruitment against
targets, and monitor data collection completeness and
quality on a day-to-day basis.
Throughout the trial, there will be central monitoring,
overseen by the TMC and DSMC, ensuring good com-
munication between the coordinating centre and the site
staff. Trial monitoring will be conducted by performing
a random selection of 11 (ie 10%) participants, with at
least one from each site, with an independent remote re-




The trial co-ordinating centre is the Robinson Research
Institute, The University of Adelaide, where the Chief
Investigator and Trial Co-ordinator are based.
Trial Management Committee (TMC)
The trial will be supervised on a day-to-day basis by the
trial management committee, which is responsible to the
trial sponsor. At each participating centre, a local PI will
report to the TMC.
The TMC will meet at least monthly and consist of
the CI and Trial Co-ordinator, an obstetrician and an




Core Investigator Group (CIG)
The CIG will meet via teleconference at least four times
a year. This will comprise all co-applicants and the
members of the TMC.
Data Safety Monitoring Committee (DSMC)
A data safety monitoring committee (DSMC) has been
established with an independent obstetrician, a neonat-
ologist and a statistician to ensure the wellbeing of study
participants. The DSMC will review the progress and
safety aspects of the trial at least annually and provide
advice on the conduct of the trial to the TMC and (via
the TMC) to the sponsor. The Chair of the DSMC will
review SAE reports and a list of protocol breaches as re-
ceived and will call a meeting of the DSMC to consider
if there is evidence of potential harm from either of the
interventions or from the conduct of the trial. The
DSMC will otherwise review listing of all AEs, SAEs, de-
viations and breaches three monthly. No interim analysis
will be performed, given the small sample size. The con-
tent and timings of the DSMC reviews are detailed in a




The results of the trial will be presented at an inter-
national meeting, likely the biennial meeting of the
International Society of Obstetric Medicine, and will
be offered for publication to leading international
clinical journals. They will be disseminated to import-
ant stakeholders, including the consumer group, ICP
Support, and transmitted to those responsible for cre-
ation and updating of clinical guidelines for patient
management, such as the Royal College of Obstetri-
cians and Gynaecologists, and the Royal Australian
and New Zealand College of Obstetricians and
Gynaecologists.
The success of the trial depends on a large number of
midwives, obstetricians and participants. Credit for the
trial findings will be given to all those who have collabo-
rated and participated in the study including all local co-
ordinators and collaborators, members of trial
committees and study staff.
Discussion
Our study will be the first to examine the outcomes of
treatment specifically in the severe early onset form of
ICP, comparing “standard” UDCA therapy with rifampi-
cin, and so be able to provide for the first-time high-
quality evidence for use of rifampicin in severe ICP. It
will also allow an assessment of feasibility of a future
trial to test whether elective early delivery in severe ICP
is beneficial.
Recruitment is underway, despite the difficulties of
the current pandemic, which have delayed many cen-
tres from embarking on new research that is unre-
lated to COVID-19 or even considering undertaking
it. We applaud all the research governance offices
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who have been willing to enable this important trial,
which has the potential to impact on the lives of the
women affected by a rare disorder of pregnancy and,
in due course, to enable further trials to examine the
bigger and more difficult questions of how to improve
pregnancy outcome.
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12884-020-03481-y.
Additional file 1:. The approved master PICF for the TURRIFIC trial is
attached as an appendix, together with a copy of the DSMC charter and
the SPIRIT checklist.
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